Likuiditas cepet longboardpharma.com (LBPH)

Longboard Pharmaceuticals (LBPH) specializes in developing therapies for rare forms of epilepsy, leveraging patent exclusivity to maintain pricing power. The business's financial stability is supported by a substantial cash reserve and strategic capital, with the key metric standing at 15.18. However, the model relies on third-party contractors for manufacturing and research. The price trend shown below illustrates the price action of this biopharmaceutical asset.

The ratio is calculated as the sum of cash and accounts receivable divided by current liabilities. This metric determines a company's ability to settle debts instantly, excluding slow-moving inventory from the analysis. For Longboard Pharmaceuticals (LBPH), this is critical, as investments in AI bioanalysis platforms require constant access to liquid funds. The trend of the quick ratio reflects financial stability during the scaling of development.